The dismal science returns: How do you make GLP-1 RAs worth taxpayers’ money?
One politician denied dreaming of a future where 'I involuntarily jab unemployed people who are overweight'.
There are many wondrous things about GLP-1 receptor agonists, not least their capacity to cripple health budgets.
Given the scale of obesity and its economic cost, governments around the globe have been wrestling with whether to fund the treatments through a variety of cost-benefit formulations.
